SEATTLE, July 22, 2021, (MEDGADGET) — Global Recombinant Human Endostatin Market Analysis
Overview
Endostatin is a protein found in most of the body’s Basement Membranes (BMs), including vascular basement membranes. The remarkable survival advantages of recombinant human endostatin in curing late-stage NSCLC (Non-Small-Cell Lung Carcinoma) have been verified in an array of medical investigations. As a result, the State Food and Drug Administration of China authorized recombinant human endostatin for the treatment of NSCLC in September 2005. Endostatin is found in a variety of organs, with the largest concentrations in the liver, lungs, and bladder.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/2262
Drivers
During the forecast period, government attempts to lower the cost of anticancer medications are expected to propel the global recombinant human endostatin market forward. In August 2018, the Chinese government announced plans to cut anticancer medicine prices by 44%. The Chinese National Health and Family Planning Commission arranged a national drug pricing and subsidy drug list negotiation, and a total of 39 goods, comprising recombinant human endostatin, were successfully included.
The global recombinant human endostatin market is forecast to rise due to increased research and development initiatives aimed at discovering potential uses for recombinant human endostatin. A research was done to analyze the influence of recombinant human endostatin in conjunction with irradiation for treating esophageal squamous cell cancer and to determine its probable mechanisms, according to a report published in the journal Nature in September 2015. These data indicate that recombinant human endostatin, when paired with radiation, might be a promising anti-angiogenic drug in esophageal squamous cell cancer.
In addition, as per the National Center for Biotechnology Information (NCBI), recombinant human endostatin in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) may help cure Angioimmunoblastic T Cell Lymphoma (AITL), a kind of Peripheral T Cell Lymphoma (PTCL). Such innovative PTCL medicines are urgently needed to enhance the results of people suffering from this illness. The global recombinant human endostatin market is estimated to expand as a result of these causes.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2262
Restraints
The global recombinant human endostatin market is projected to be hampered by rising hurdles in large-scale synthesis of recombinant human endostatin. As per a paper published by the National Center for Biotechnology Information (NCBI) in April 2017, tumor therapy necessitates huge quantities of biologically active recombinant human endostatin, which necessitates enormous quantities of recombinant human endostatin manufacturing. This procedure is tough since it relies on recombinant DNA technology and has a poor accuracy rate in cancer treatment. In addition, recombinant human endostatin is expensive and has a limited half-life. Endostatin is unstable because the purifying process might denature its structure, resulting in poor yields.
Regional Analysis
Due to the rising frequency of cancer in the U.S., North America is projected to have a dominating position in the global recombinant human endostatin market during the forecast period. As per the Centers for Disease Control and Prevention (CDC), there were approximately 1,633,390 new cancer cases recorded in the U.S. in 2015, with the number anticipated to rise to 1,735,350 in 2018.
Moreover, due to an increase in the number of clinical studies for recombinant human endostatin, Asia Pacific is expected to develop significantly in the global recombinant human endostatin market over the forecast period. The PLA General Hospital in China is conducting a clinical phase II trial for the treatment of Hepatocellular Carcinoma using recombinant human endostatin and radiation. The research began in January 2017 and is expected to end in December 2019.
Furthermore, a clinical phase II trial employing chemotherapy and Endostar is being conducted at Yun-fei Xia University in China (endostatin). Endostar is an intravenous infusion that is used to treat resistant nasopharyngeal cancer. The research began in July 2015 and will be completed in December 2020.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/2262
Competitive Landscape
Major companies contributing in the global recombinant human endostatin market are FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Yantai Medgenn Ltd., Thermo Fisher Scientific, Biocon, Novus Biologicals, Pfizer Inc., Novartis AG, Intas Pharmaceuticals Ltd., Hetero, Genexine, Inc., Onyx Pharmaceuticals, Inc., and PeproTech, Inc.
Table of Content
Global Recombinant Human Endostatin Market Research Report
Section 1: Global Recombinant Human Endostatin Industry Overview
Section 2: Global Economic Impact on Recombinant Human Endostatin Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Recombinant Human Endostatin Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Recombinant Human Endostatin Market Forecast
Other Exclusive Reports:
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837